249 related articles for article (PubMed ID: 28302567)
1. Alpha
Castillo LF; Rivero EM; Goffin V; Lüthy IA
Cell Signal; 2017 Jun; 34():76-85. PubMed ID: 28302567
[TBL] [Abstract][Full Text] [Related]
2. Prolactin Signaling Stimulates Invasion via Na(+)/H(+) Exchanger NHE1 in T47D Human Breast Cancer Cells.
Pedraz-Cuesta E; Fredsted J; Jensen HH; Bornebusch A; Nejsum LN; Kragelund BB; Pedersen SF
Mol Endocrinol; 2016 Jul; 30(7):693-708. PubMed ID: 27176613
[TBL] [Abstract][Full Text] [Related]
3. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
Kavarthapu R; Tsai Morris CH; Dufau ML
Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
[TBL] [Abstract][Full Text] [Related]
4. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
[TBL] [Abstract][Full Text] [Related]
5. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
[TBL] [Abstract][Full Text] [Related]
6. STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis.
Yang X; Meyer K; Friedl A
J Biol Chem; 2013 Jul; 288(29):21184-21196. PubMed ID: 23729680
[TBL] [Abstract][Full Text] [Related]
7. The role of prolactin receptor in GH signaling in breast cancer cells.
Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
[TBL] [Abstract][Full Text] [Related]
8. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.
Langenheim JF; Tan D; Walker AM; Chen WY
Mol Endocrinol; 2006 Mar; 20(3):661-74. PubMed ID: 16269515
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
10. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
11. Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer.
Nitze LM; Galsgaard ED; Din N; Lund VL; Rasmussen BB; Berchtold MW; Christensen L; Panina S
Breast Cancer Res Treat; 2013 Nov; 142(1):31-44. PubMed ID: 24146212
[TBL] [Abstract][Full Text] [Related]
12. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
13. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
14. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways.
Um M; Lodish HF
J Biol Chem; 2006 Mar; 281(9):5648-56. PubMed ID: 16407271
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells.
Cataldo L; Chen NY; Yuan Q; Li W; Ramamoorthy P; Wagner TE; Sticca RP; Chen WY
Int J Oncol; 2000 Dec; 17(6):1179-85. PubMed ID: 11078803
[TBL] [Abstract][Full Text] [Related]
16. Human breast cell lines exhibit functional alpha2-adrenoceptors.
Vázquez SM; Mladovan AG; Pérez C; Bruzzone A; Baldi A; Lüthy IA
Cancer Chemother Pharmacol; 2006 Jul; 58(1):50-61. PubMed ID: 16292538
[TBL] [Abstract][Full Text] [Related]
17. Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells.
Aksamitiene E; Achanta S; Kolch W; Kholodenko BN; Hoek JB; Kiyatkin A
Cell Signal; 2011 Nov; 23(11):1794-805. PubMed ID: 21726627
[TBL] [Abstract][Full Text] [Related]
18. JAK2/STAT5 Pathway Mediates Prolactin-Induced Apoptosis of Lactotropes.
de Dios N; Orrillo S; Irizarri M; Theas MS; Boutillon F; Candolfi M; Seilicovich A; Goffin V; Pisera D; Ferraris J
Neuroendocrinology; 2019; 108(2):84-97. PubMed ID: 30376668
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL.
Schroeder MD; Brockman JL; Walker AM; Schuler LA
Endocrinology; 2003 Dec; 144(12):5300-7. PubMed ID: 12970160
[TBL] [Abstract][Full Text] [Related]
20. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
Lim JH; Kim TY; Kim WH; Park JW
Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
